Today: 9 June 2026
Circle (CRCL) stock jumps again after hours as Mizuho lifts target to $100 on oil, rate worries
3 March 2026
2 mins read

Circle (CRCL) stock jumps again after hours as Mizuho lifts target to $100 on oil, rate worries

New York, March 3, 2026, 5:16 PM EST — Trading after the bell.

  • Shares rose as much as $104.30 before pulling back; last up 3.6% at $99.63
  • Mizuho bumped its Circle price target up to $100, pointing to dwindling chances of the Fed cutting rates anytime soon.
  • CFO Jeremy Fox-Geen filed a Form 144, signaling a modest planned sale under Rule 144.

Circle Internet Group (CRCL) climbed 3.6% to $99.63 in after-hours trading on Tuesday, building on a two-day rally that followed Mizuho’s price target hike for the stablecoin issuer. Earlier in the session, shares reached as high as $104.30. Volume was hefty—roughly 33 million shares changed hands.

Circle is the company behind USD Coin, or USDC, a stablecoin pegged one-to-one with the U.S. dollar. Cash backing the tokens goes mostly into short-term Treasuries and deposits. That means Circle’s profits shift with U.S. interest rates.

Traders are once again watching that link, trying to gauge if the Federal Reserve is positioned to cut rates soon. Oil prices, meanwhile, are climbing as Middle East tensions persist.

Dan Dolev at Mizuho Securities bumped his price target up to $100 from $90 but stuck with a neutral call, warning that oil-driven inflation could delay rate cuts. “Rising oil prices could drive up inflation, lowering the odds of rate cuts,” Dolev said. TheStreet

Circle shares surged 15.2% Monday, pushing its post-earnings rally further and cementing the stock’s reputation as a go-to gauge for rates and crypto moves among traders. Gains cooled off late Tuesday, though Circle still closed the session above water.

Chief Financial Officer Jeremy Fox-Geen signaled plans to offload 4,238 Class A shares, according to a Form 144 filed Tuesday, the shares linked to a March 1 restricted stock vesting. The same document pointed to earlier transactions: Fox-Geen sold 47,908 shares on Feb. 26, then another 7,200 on March 2. The filing cited a Rule 10b5-1 trading plan, put into place in August 2025. Form 144 serves as advance notice for company insiders aiming to sell stock under SEC Rule 144, which governs the resale of certain securities.

Circle’s most recent moves follow last week’s earnings surprise, as the company topped Wall Street estimates thanks to a 72% surge in USDC circulation, now at $75.3 billion, and $733 million in reserve income. “The key takeaway is that USDC continues scaling rapidly,” Seaport Research Partners analyst Jeff Cantwell said at the time. CEO Jeremy Allaire told Reuters he’d “welcome” additional rate cuts, even though higher rates pad reserve income. Reuters

Circle puts its stablecoin reserves into short-term government debt and cash, pocketing the yield—so it stands to gain when policy remains tight. That setup also lets the stock sometimes move in line with short-term rates, especially on quieter crypto news days.

But when markets swing risk-off, crypto activity tends to get squeezed, and demand for stablecoins often drops. Circle is also up against rival dollar-backed tokens and payments companies moving further into blockchain settlement.

Still, the trade can unwind fast. If oil prices tumble or softer U.S. numbers push up hopes for earlier rate cuts, Circle’s reserve income outlook takes a hit. More insider selling could also dump extra supply onto shares that have already surged in little time.

Focus shifts now to fresh U.S. numbers and what’s next out of the Fed. Traders are keyed in on Friday’s jobs data (March 6), then the CPI for February coming March 11. All eyes, of course, on the Fed’s policy meeting set for March 17–18.

Stock Market Today

  • Rocket Lab Stock Price Forecast: AI Analyst Cautions Despite 60% Surge
    June 9, 2026, 10:12 AM EDT. Shares of Rocket Lab USA ($RKLB) have jumped more than 60% year-to-date due to increased demand for small-satellite launches. Despite the rally, AI-driven analysis from TipRanks highlights caution, urging investors to consider potential market volatility and competitive pressures. Rocket Lab's growth taps into expanding satellite deployment, but risks remain in a crowded aerospace sector. Investors should balance optimism with these cautionary signals from advanced analytics.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
MARA stock jumps premarket as annual filing opens door to selling bitcoin stash
Previous Story

MARA stock jumps premarket as annual filing opens door to selling bitcoin stash

CrowdStrike stock holds steady after upbeat 2027 forecast as Wall Street sizes up ARR
Next Story

CrowdStrike stock holds steady after upbeat 2027 forecast as Wall Street sizes up ARR

Go toTop